Combination pravastatin and valsartan treatment has additive beneficial effects to simultaneously improve both metabolic and cardiovascular phenotypes beyond that of monotherapy with either drug in patients with primary hypercholesterolemia. - Wikidata - wikimedia - TriplyDB

Combination pravastatin and valsartan treatment has additive beneficial effects to simultaneously improve both metabolic and cardiovascular phenotypes beyond that of monotherapy with either drug in patients with primary hypercholesterolemia.

Combination pravastatin and valsartan treatment has additive beneficial effects to simultaneously improve both metabolic and cardiovascular phenotypes beyond that of monotherapy with either drug in patients with primary hypercholesterolemia.

http://www.wikidata.org/entity/Q37193394

about

Regulation of glucose and lipid homeostasis by adiponectin: effects on hepatocytes, pancreatic β cells and adipocytes Longitudinal associations between adiponectin and cardiac structure differ by hypertensive status: Coronary Artery Risk Development in Young Adults.Hypercholesterolemia and Hypertension: Two Sides of the Same Coin.Combining Potent Statin Therapy with Other Drugs to Optimize Simultaneous Cardiovascular and Metabolic Benefits while Minimizing Adverse Events.Angiotensin converting enzyme inhibitors remain the first treatment of choice.The effect of atorvastatin treatment duration on oxidative stress markers and lipid profile in patients with coronary artery diseases: A case series study.

P2860

Q35683960-2B1C0E40-64A4-460B-8B95-4EFB9FE51178 Q37166681-6599D05A-937D-4958-8107-4BB909DFCE9C Q38524257-F9AA3D4B-95CC-4F49-8742-8D82840D25C7 Q41190859-C8336975-D700-430C-A3CF-BF931F6D177C Q42617282-EB67CB20-A09F-4B9A-A4E1-90CAEB50847A Q55128005-A7296A35-5109-435E-AF47-2B9F21402E8C

P2860

Combination pravastatin and valsartan treatment has additive beneficial effects to simultaneously improve both metabolic and cardiovascular phenotypes beyond that of monotherapy with either drug in patients with primary hypercholesterolemia.

http://www.wikidata.org/entity/Q37193394

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 17 July 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Combination pravastatin and va ...... primary hypercholesterolemia.

@en

Combination pravastatin and va ...... primary hypercholesterolemia.

@nl

type

label

Combination pravastatin and va ...... primary hypercholesterolemia.

@en

Combination pravastatin and va ...... primary hypercholesterolemia.

@nl

prefLabel

Combination pravastatin and va ...... primary hypercholesterolemia.

@en

Combination pravastatin and va ...... primary hypercholesterolemia.

@nl

P1433

Q37193394-6C03F63B-E07D-4B5A-AA1A-D5FFA65C7119

P1476

Q37193394-03AD516D-628E-4718-AECD-473B621242AF

P2093

Q37193394-24155402-8310-4A8D-B030-AB62B6E2D895

Q37193394-50378D0A-8013-47E5-9FE8-6EAC440BD5E0

Q37193394-5A0BFE93-BCE4-4EA0-A9C9-61A169DD86FA

Q37193394-6C592629-32D6-4F65-B642-707C0F01C1CC

Q37193394-BBF2F6ED-8562-460C-B10A-10D05BEF933E

Q37193394-C3049642-1526-4732-8AE0-1302A96766E3

Q37193394-DCE9091F-77AD-4793-BB25-CFD575CBDF35

Q37193394-E7F848C4-8586-4DF3-ACFD-9F1C9765DB2A

Q37193394-F649A8E8-7749-4624-811A-77558BC426EC

P2860

Q37193394-1B98313D-18B9-4E66-9AC9-1AF3118C9CCC

Q37193394-355F1DF3-10E0-433B-ACD8-593FA69D1DAE

Q37193394-44372891-EC29-44F1-A1F2-6DA258807BE6

Q37193394-54EAD888-2402-45C4-89FC-2A38B76C9B96

Q37193394-54F4B5A7-C3DC-4A5D-A66A-70FDA6E099EE

Q37193394-5601B2A4-7539-4DF6-B040-764CFC7B7824

Q37193394-57ADC798-EF48-44A2-AD63-9D1DBA9DEFA0

Q37193394-6923BEE2-C344-4C9C-98B0-4A67B92EF1AD

Q37193394-7228731A-BE9E-4A83-BF92-C7467F4EC74B

Q37193394-81667F78-E15C-46EF-BBB7-AFB774972C9F

P304

Q37193394-C3DD604C-81FC-49D0-8013-364F4A4F21B0

P31

Q37193394-CF8DAD83-E996-4F5F-BDB6-E284BF1F8616

P356

Q37193394-1A2EDD18-F8DB-45B2-B997-772EFBB44256

P407

Q37193394-A4389911-7782-44E8-A545-BB86BEAB0BCD

P433

Q37193394-EB15BE26-8835-4DD1-81DC-A21346CA2426

P478

Q37193394-E025F59C-EF10-4897-BEDA-161BEFE409A0

P50

Q37193394-BA99F310-0D1A-49E7-84F9-F962053DCA14

Q37193394-CC544112-8ED3-4740-9CB0-21C43773C740

P577

Q37193394-32043D11-B3A0-41EC-A2ED-26FD97FF0246

P5875

Q37193394-E704A0B4-2836-48EA-8868-A77E3F3E177D

P698

Q37193394-1422CB5B-D688-4112-A294-C641F0B82658

P921

Q37193394-43B2259B-A10F-42F5-97EB-F58A8149E5B0

P932

Q37193394-1C70176E-6756-4B6F-A07B-9FBF73020A32

P356

P1433

P1476

Combination pravastatin and va ...... primary hypercholesterolemia.

@en

P2093

Eak Kyun Shin

http://www.w3.org/2001/XMLSchema#string

Hanul Choi

http://www.w3.org/2001/XMLSchema#string

Kwang Kon Koh

http://www.w3.org/2001/XMLSchema#string

Kyounghoon Lee

http://www.w3.org/2001/XMLSchema#string

Michael J Quon

http://www.w3.org/2001/XMLSchema#string

Pyung Chun Oh

http://www.w3.org/2001/XMLSchema#string

Seung Hwan Han

http://www.w3.org/2001/XMLSchema#string

Yonghee Lee

http://www.w3.org/2001/XMLSchema#string

P2860

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report

Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study.

Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans.

Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability.

Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis.

Simvastatin improves flow-mediated dilation but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients

Combination therapy for treatment or prevention of atherosclerosis: focus on the lipid-RAAS interaction

Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients.

Diabetes and cause-specific mortality in a prospective cohort of one million U.S. adults

Reciprocal relationships between abnormal metabolic parameters and endothelial dysfunction.

P304

3547-3552

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DB13-0566

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

62

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-07-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

249996795

http://www.w3.org/2001/XMLSchema#string

P698

23863812

http://www.w3.org/2001/XMLSchema#string

P921

hypercholesterolemia

P932

3781478

http://www.w3.org/2001/XMLSchema#string